Laforin (EPM2, Epilepsy Progressive Myoclonus Type 2 Lafora Disease (Laforin), Epilepsy Progressive Myoclonus Type 2A Lafora Disease (Laforin), EPM2, Epm2a, Lafora PTPase, LAFPTPase, LD, LDE, MELF)

Laforin, also known as Lafora PTPase, is a dual specificity protein phosphatase. Laforin is involved in the control of glycogen metabolism, specifically in preventing the formation of poorly branched glycogen molecules (polyglucosans). Laforin forms a complex with NHLRC1/malin and HSP70 that suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system (UPS). Laforin is expressed in heart, skeletal muscle, kidney, pancreas and brain. Defective Laforin is linked to progressive myoclonic epilepsy type 2 (EPM2).||Applications: |Suitable for use in Western Blot, Immunocytochemistry/Immunofluorescence. Other applications not tested.||Recommended Dilution:|Western Blot: 1:1000|Optimal dilutions to be determined by the researcher.||Storage and Stability:|May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.